Florian Krammer
#77,871
Most Influential Person Now
Researcher
Florian Krammer's AcademicInfluence.com Rankings
Florian Krammerbiology Degrees
Biology
#3865
World Rank
#5854
Historical Rank
Virology
#63
World Rank
#66
Historical Rank
Microbiology
#122
World Rank
#146
Historical Rank
Immunology
#164
World Rank
#172
Historical Rank
Download Badge
Biology
Florian Krammer's Degrees
- PhD Microbiology University of Vienna
- Masters Microbiology University of Vienna
Why Is Florian Krammer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Florian Krammer is an Austrian-American virologist who has been Endowed Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai since 2019. He was trained at the University of Natural Resources and Life Sciences in Vienna, Austria, where his mentor was Reingard Grabherr. He then completed his postdoc at Icahn under the supervision of Peter Palese. He has been the principal investigator of the Sinai-Emory Multi-Institutional Collaborative Influenza Vaccine Innovation Center since 2019.
Florian Krammer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals (2020) (2848)
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (2021) (1934)
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 (2020) (1524)
- SARS-CoV-2 vaccines in development (2020) (1405)
- A serological assay to detect SARS-CoV-2 seroconversion in humans (2020) (1067)
- SARS-CoV-2 Vaccines: Status Report (2020) (954)
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for months (2020) (939)
- A serological assay to detect SARS-CoV-2 seroconversion in humans (2020) (879)
- Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development (2020) (773)
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup (2020) (594)
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine (2021) (590)
- Influenza (2018) (502)
- Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity (2017) (439)
- SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) (430)
- Introductions and early spread of SARS-CoV-2 in the New York City area (2020) (366)
- Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study (2020) (364)
- Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies (2013) (348)
- The human antibody response to influenza A virus infection and vaccination (2019) (342)
- Immune history profoundly affects broadly protective B cell responses to influenza (2015) (317)
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron (2021) (312)
- Influenza virus hemagglutinin stalk-based antibodies and vaccines. (2013) (301)
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses (2018) (292)
- Advances in the development of influenza virus vaccines (2015) (289)
- Serology assays to manage COVID-19 (2020) (267)
- Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) (2020) (258)
- SARS-CoV-2 spike E484K mutation reduces antibody neutralisation (2021) (253)
- Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) (2020) (252)
- Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses (2012) (252)
- Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies (2018) (243)
- Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination (2016) (236)
- SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation (2020) (233)
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (2021) (232)
- Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes (2012) (232)
- The first 12 months of COVID-19: a timeline of immunological insights (2021) (231)
- Advances in the development of influenza virus vaccines (2015) (222)
- Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. (2016) (214)
- Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans (2014) (203)
- A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice (2020) (201)
- A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses (2017) (190)
- Scientific consensus on the COVID-19 pandemic: we need to act now (2020) (185)
- Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A Viruses (2013) (181)
- From Original Antigenic Sin to the Universal Influenza Virus Vaccine. (2018) (176)
- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) (167)
- Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis (2013) (162)
- Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk (2020) (161)
- A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection (2020) (158)
- Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies (2018) (158)
- Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility (2013) (155)
- Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice (2015) (153)
- Immunological memory to SARS-CoV-2 assessed for up to eight months after infection (2020) (152)
- A Carboxy-Terminal Trimerization Domain Stabilizes Conformational Epitopes on the Stalk Domain of Soluble Recombinant Hemagglutinin Substrates (2012) (150)
- Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy (2015) (148)
- Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection (2018) (148)
- H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice (2013) (145)
- A correlate of protection for SARS-CoV-2 vaccines is urgently needed (2021) (144)
- NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? (2018) (143)
- A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo (2012) (143)
- SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact (2021) (143)
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma (2021) (143)
- In the Shadow of Hemagglutinin: A Growing Interest in Influenza Viral Neuraminidase and Its Role as a Vaccine Antigen (2014) (141)
- An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening (2020) (141)
- Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. (2013) (141)
- Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans (2014) (140)
- SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting (2021) (140)
- Universal influenza virus vaccines and therapeutic antibodies. (2017) (139)
- The influenza virus hemagglutinin head evolves faster than the stalk domain (2018) (138)
- A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial (2020) (138)
- Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus (2016) (133)
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months (2020) (130)
- Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine (2021) (129)
- Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study (2020) (128)
- A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. (2020) (126)
- Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets (2014) (126)
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses (2021) (126)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models (2021) (124)
- Human germinal centres engage memory and naïve B cells after influenza vaccination (2020) (123)
- Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection (2016) (121)
- Trichoplusia ni cells (High FiveTM) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines (2010) (117)
- Convalescent plasma treatment of severe COVID-19: A matched control study (2020) (117)
- The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. (2021) (116)
- Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice (2017) (115)
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City (2020) (114)
- Broadly protective human antibodies that target the active site of influenza virus neuraminidase (2019) (113)
- Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. (2015) (113)
- Novel correlates of protection against pandemic H1N1 influenza A virus infection (2019) (110)
- Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans (2016) (109)
- Immunological imprinting of the antibody response in COVID-19 patients (2021) (105)
- A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies (2017) (105)
- Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. (2015) (104)
- Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin (2017) (103)
- The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera (2021) (102)
- Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin (2014) (102)
- Animal Models for Influenza Viruses: Implications for Universal Vaccine Development (2014) (101)
- Defining the antibody cross-reactome against the influenza virus surface glycoproteins (2017) (101)
- Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact (2016) (100)
- H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge (2013) (100)
- Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers (2018) (99)
- Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice (2012) (98)
- Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals. (2019) (98)
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses (2020) (96)
- Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes (2017) (92)
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region (2020) (91)
- Systems serology detects functionally distinct coronavirus antibody features in children and elderly (2021) (89)
- Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection (2020) (86)
- Novel universal influenza virus vaccine approaches. (2016) (85)
- Correlates of protection from SARS-CoV-2 infection (2021) (84)
- Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial (2019) (83)
- CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity (2021) (82)
- Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses (2015) (81)
- 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. (2013) (80)
- Dengue Virus Immunity Increases Zika Virus‐Induced Damage during Pregnancy (2019) (78)
- Domestic Pigs Are Susceptible to Infection with Influenza B Viruses (2015) (77)
- Evidence of a significant secretory-IgA-dominant SARS-CoV-2 immune response in human milk following recovery from COVID-19 (2020) (77)
- MHC class II proteins mediate cross-species entry of bat influenza viruses (2019) (77)
- Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets (2021) (77)
- Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection (2020) (77)
- SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike (2020) (76)
- Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. (2020) (74)
- Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. (2015) (74)
- Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma (2020) (74)
- Neutralizing Antibody Responses in COVID-19 Convalescent Sera (2020) (73)
- Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination (2016) (72)
- Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs (2013) (70)
- Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets (2015) (70)
- Universal influenza virus vaccines: need for clinical trials (2013) (69)
- B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination (2013) (68)
- H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. (2013) (67)
- An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin‐Bearing Influenza Viruses (2017) (67)
- Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication (2017) (67)
- One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge (2014) (66)
- A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice (2016) (66)
- Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine. (2018) (66)
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate (2020) (66)
- Residual Baculovirus in Insect Cell-Derived Influenza Virus-Like Particle Preparations Enhances Immunogenicity (2012) (64)
- Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (64)
- Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model (2017) (64)
- Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice (2015) (63)
- Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model (2017) (63)
- Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera (2020) (62)
- Adjuvants and Immunization Strategies to Induce Influenza Virus Hemagglutinin Stalk Antibodies (2013) (62)
- Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge (2014) (59)
- Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
- Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2 (2020) (58)
- Emerging influenza viruses and the prospect of a universal influenza virus vaccine (2015) (58)
- Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice (2019) (57)
- Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination (2021) (57)
- Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin (2013) (57)
- Alternative influenza vaccines made by insect cells. (2010) (56)
- Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans (2020) (53)
- Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain. (2019) (53)
- mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions (2022) (53)
- NS1-Truncated Live Attenuated Virus Vaccine Provides Robust Protection to Aged Mice from Viral Challenge (2012) (53)
- An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans (2014) (52)
- Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. (2020) (52)
- Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus (2019) (51)
- Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses (2015) (50)
- SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors (2021) (49)
- Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. (2017) (49)
- Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections (2017) (48)
- The Quest for a Universal Flu Vaccine: Headless HA 2.0. (2015) (48)
- Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City (2020) (47)
- Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers (2021) (46)
- Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma (2021) (46)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques (2021) (45)
- Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs (2019) (45)
- mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern (2022) (45)
- Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses (2020) (44)
- Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults (2020) (43)
- Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans (2020) (43)
- Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies (2018) (43)
- The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain (2019) (43)
- High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. (2015) (43)
- Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance (2018) (42)
- Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA (2021) (41)
- The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD (2021) (41)
- COVID-19: Staging of a New Disease (2020) (41)
- Development of Influenza B Universal Vaccine Candidates Using the “Mosaic” Hemagglutinin Approach (2019) (41)
- Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus (2019) (41)
- Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model (2019) (40)
- Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak (2020) (40)
- Purification of infective baculoviruses by monoliths. (2013) (40)
- Mapping SARS-CoV-2 antigenic relationships and serological responses (2022) (40)
- Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak (2020) (39)
- Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge (2019) (39)
- Swine‐origin pandemic H1N1 influenza virus‐like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice (2010) (39)
- Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans (2017) (38)
- Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults (2019) (38)
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron (2021) (37)
- New England harbor seal H3N8 influenza virus retains avian-like receptor specificity (2016) (37)
- Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins (2016) (37)
- Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model (2021) (37)
- A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants (2021) (37)
- A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine (2020) (37)
- Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains (2015) (37)
- Distinct systems serology features in children, elderly and COVID patients (2020) (36)
- Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells (2015) (36)
- Insect cells for antibody production: evaluation of an efficient alternative. (2011) (36)
- Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine (2019) (36)
- A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses (2021) (36)
- Efficient Transmission of Pandemic H1N1 Influenza Viruses with High-Level Oseltamivir Resistance (2012) (35)
- Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans (2017) (34)
- Broadly neutralizing antibodies target a haemagglutinin anchor epitope (2021) (34)
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations (2022) (33)
- Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza (2018) (33)
- High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination (2015) (33)
- Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus? (2018) (33)
- Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model (2017) (32)
- Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses (2018) (32)
- Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study (2021) (32)
- A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine (2020) (32)
- Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination (2021) (32)
- Meeting report and review: Immunological assays and correlates of protection for next‐generation influenza vaccines (2019) (31)
- Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients (2021) (31)
- Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection (2017) (31)
- Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity (2017) (30)
- Strategies to induce broadly protective antibody responses to viral glycoproteins (2017) (30)
- Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice (2019) (30)
- Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. (2020) (29)
- Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19 (2020) (29)
- Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. (2020) (28)
- Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin. (2018) (28)
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains (2021) (28)
- Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice (2019) (28)
- Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines (2021) (28)
- Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate (2021) (28)
- Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern (2021) (27)
- The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines (2013) (27)
- A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains (2019) (27)
- Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate (2016) (27)
- Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine (2021) (26)
- A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study (2018) (26)
- Antibody Immunological Imprinting on COVID-19 Patients (2020) (26)
- Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors (2021) (25)
- A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine (2014) (25)
- Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model (2020) (25)
- An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations (2018) (25)
- Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model (2018) (24)
- Inhibition of HECT E3 ligases as potential therapy for COVID-19 (2021) (24)
- Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features (2021) (24)
- SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals (2022) (24)
- Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice (2018) (23)
- SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study (2020) (23)
- SARS-CoV-2-specific IgA and limited inflammatory cytokines are present in the stool of select patients with acute COVID-19 (2020) (23)
- Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice (2017) (23)
- Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice (2018) (23)
- Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. (2010) (22)
- Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge (2018) (22)
- Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19 (2021) (22)
- Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. (2020) (22)
- Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs (2021) (22)
- Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts (2019) (22)
- First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes (2021) (21)
- A replication competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. (2021) (20)
- Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37 (2021) (20)
- Attenuated Influenza Virus Construct with Enhanced Hemagglutinin Protein Expression (2012) (20)
- Efficient mucosal antibody response to SARS-CoV-2 vaccination is induced in previously infected individuals (2021) (20)
- Is It Possible to Develop a “Universal” Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development (2017) (20)
- Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans (2018) (20)
- Influenza Virus Infection in Guinea Pigs Raised as Livestock, Ecuador (2012) (20)
- Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model (2020) (20)
- Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus (2016) (19)
- Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2 (2020) (19)
- Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model (2019) (19)
- Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era (2019) (19)
- Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination (2016) (19)
- Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients (2022) (19)
- Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses (2022) (18)
- Development of an influenza virus protein microarray to measure the humoral response to influenza virus infection in mallards (2017) (18)
- Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models (2020) (17)
- A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. (2021) (17)
- An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13. (2015) (17)
- Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation (2021) (17)
- Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein (2019) (16)
- Anti‐SARS‐CoV‐2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks (2020) (16)
- Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial (2022) (16)
- Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study (2019) (16)
- Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination (2021) (16)
- SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital — New York City, April 2020 (2021) (16)
- A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2 (2020) (16)
- Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals (2022) (16)
- SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike (2021) (16)
- Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike (2021) (16)
- Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection In Vitro and in a Mouse Model (2018) (15)
- Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model (2021) (15)
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains (2021) (15)
- A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants (2021) (15)
- Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico (2022) (14)
- Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice (2021) (14)
- Transfusion reactions associated with COVID‐19 convalescent plasma therapy for SARS‐CoV‐2 (2020) (14)
- Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination (2019) (14)
- Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase (2019) (14)
- Correctly folded - but not necessarily functional - influenza virus neuraminidase is required to induce protective antibody responses in mice. (2020) (14)
- Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles (2021) (13)
- Hemagglutinin Receptor Binding of a Human Isolate of Influenza A(H10N8) Virus (2015) (13)
- Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. (2017) (13)
- Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models (2022) (12)
- Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial (2022) (12)
- Emerging from the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination. (2019) (12)
- Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination (2021) (12)
- Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals (2020) (12)
- Characterization of swine-origin H1N1 canine influenza viruses (2019) (12)
- Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients (2020) (12)
- SARS‐CoV‐2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort (2021) (12)
- Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR (2022) (12)
- Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model (2021) (11)
- Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses? (2017) (11)
- Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. (2018) (11)
- Generation of a serum free CHO DG44 cell line stably producing a broadly protective anti-influenza virus monoclonal antibody (2017) (11)
- A 10-Minute “Mix and Read” Antibody Assay for SARS-CoV-2 (2021) (11)
- A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies (2018) (11)
- Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study (2022) (11)
- An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains (2019) (11)
- A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) (2020) (11)
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate (2020) (11)
- A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice (2022) (10)
- SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection (2022) (10)
- SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans (2021) (10)
- Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot (2022) (10)
- Seroconversion in household members of COVID-19 outpatients (2020) (10)
- SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity (2022) (10)
- A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model (2021) (10)
- Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement (2020) (10)
- Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave (2021) (10)
- The Spike-specific IgA in milk commonly-elicited after SARS-Cov-2 infection is concurrent with a robust secretory antibody response, exhibits neutralization potency strongly correlated with IgA binding, and is highly durable over time (2021) (9)
- Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera (2022) (9)
- Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus (2021) (9)
- Viral Fitness Landscapes in Diverse Host Species Reveal Multiple Evolutionary Lines for the NS1 Gene of Influenza A Viruses (2019) (9)
- Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial (2021) (9)
- Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats (2021) (9)
- Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine** (9)
- Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam (2022) (9)
- In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant (2020) (9)
- Cross-Reactive and Cross-Neutralizing Activity of Human Mumps Antibodies Against a Novel Mumps Virus From Bats (2016) (9)
- Pandemic Vaccines: How Are We Going to Be Better Prepared Next Time? (2020) (9)
- The first 12 months of COVID-19: a timeline of immunological insights (2021) (9)
- H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model (2020) (8)
- Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components (2021) (8)
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial (2021) (8)
- Influenza A viruses balance ER stress with host protein synthesis shutoff (2021) (8)
- Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect In Vivo in a Mouse Model in a Neutralization-Dependent Manner (2021) (8)
- Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase (2021) (8)
- Heterologous viral protein interactions within licensed seasonal influenza virus vaccines (2020) (8)
- Influenza B virus reverse genetic backbones with improved growth properties in the EB66® cell line as basis for vaccine seed virus generation. (2018) (8)
- Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice (2022) (8)
- Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity (2021) (8)
- Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice (2021) (7)
- Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit (2021) (7)
- Real Time Investigation of a large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology (2020) (7)
- Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients (2020) (7)
- Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera (2021) (7)
- AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets (2021) (7)
- Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus (2021) (7)
- Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies. (2017) (7)
- Hemagglutinin Stalk Antibody Responses Following Trivalent Inactivated Influenza Vaccine Immunization of Pregnant Women and Association With Protection From Influenza Virus Illness (2019) (7)
- High attack rates of SARS-CoV-2 infection through household-transmission: a prospective study (2020) (7)
- Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses (2022) (7)
- Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice (2021) (7)
- Comparative Immunogenicity of the 2014–2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children (2019) (7)
- An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization (2021) (7)
- No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination (2019) (6)
- Improved integration of single-cell transcriptome and surface protein expression by LinQ-View (2021) (6)
- Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies (2021) (6)
- Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes (2021) (6)
- Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants (2022) (6)
- A HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model (2019) (6)
- A cross‐clade H5N1 influenza A virus neutralizing monoclonal antibody binds to a novel epitope within the vestigial esterase domain of hemagglutinin (2017) (6)
- Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies (2020) (6)
- Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses (2020) (6)
- Evaluation of the Influenza A Replicon for Transient Expression of Recombinant Proteins in Mammalian Cells (2010) (6)
- Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms (2021) (6)
- A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters (2021) (6)
- The influenza virus hemagglutinin head evolves faster than the stalk domain (2018) (5)
- Refocusing the Immune Response to Selected Epitopes on a Zika Virus Protein Antigen by Nanopatterning (2021) (5)
- Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants (2022) (5)
- Divergent H 7 Immunogens Offer Protection from H 7 N 9 Virus Challenge (2014) (5)
- SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact (2021) (5)
- Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer (2022) (5)
- Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital (2021) (5)
- Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine. (2018) (5)
- Analysis Of The Vaccine-Induced Influenza B Virus Hemagglutinin-Specific Antibody Dependent Cellular Cytotoxicity Response. (2019) (5)
- Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies (2022) (5)
- PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2 (2022) (5)
- Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses (2022) (5)
- The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination (2021) (4)
- Cross-Reactive Antibodies Binding to the Influenza Virus Subtype H11 Hemagglutinin (2019) (4)
- Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. (2022) (4)
- Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence (2022) (4)
- Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses. (2018) (4)
- Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response (2021) (4)
- Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms (2021) (4)
- Differential T cell reactivity to seasonal coronaviruses and SARS-CoV-2 in community and health care workers (2021) (4)
- Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-alpha inhibitors (2021) (4)
- Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model (2021) (4)
- Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients (2021) (4)
- Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants (2021) (4)
- Heterologous viral protein interactions within licensed seasonal influenza virus vaccines. (2020) (4)
- H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets. (2018) (4)
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies (2022) (3)
- Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice. (2020) (3)
- The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination (2022) (3)
- Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages (2021) (3)
- Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection. (2021) (3)
- Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination (2021) (3)
- Immune response to 2-dose BNT162b2 vaccination and risk of SARS-CoV-2 breakthrough infection: The Shieldvacc-2 study (2022) (3)
- The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization (2022) (3)
- Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer (2022) (3)
- Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice (2022) (3)
- Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain (2022) (3)
- Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity (2020) (3)
- A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins (2022) (3)
- Antibody responses to influenza A(H1N1)pdm infection. (2020) (3)
- Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies (2018) (3)
- OA01.01 Analysis of Lung Cancer Patients Receiving SARS-CoV-2 Vaccines Revealed a Minority Subset With Poor Antibody Responses Relative to Controls (2021) (3)
- The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history. (2022) (2)
- FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection (2021) (2)
- Innovative vaccine approaches—a Keystone Symposia report (2022) (2)
- Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus (2020) (2)
- Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines (2022) (2)
- The influence of structural racism, pandemic stress, and SARS-CoV-2 infection during pregnancy with adverse birth outcomes (2022) (2)
- Human germinal centres engage memory and naive B cells after influenza vaccination (2020) (2)
- Seroprevalence of SARS-CoV-2 during pregnancy and associated outcomes: results from an ongoing prospective cohort study, New York City (2021) (2)
- Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike (2021) (2)
- Rapid homogeneous assay for detecting antibodies against SARS-CoV-2 (2020) (2)
- Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity (2021) (2)
- Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States. (2016) (2)
- Fighting influenza through hemagglutinin diversity (2019) (2)
- An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses (2020) (2)
- Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine (2020) (2)
- Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report (2021) (2)
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants (2022) (2)
- Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase (2021) (2)
- Corrigendum: Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine (2021) (2)
- Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD (2021) (2)
- High-complexity extracellular barcoding using a viral hemagglutinin (2020) (2)
- Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface (2022) (1)
- A041 DETECTION OF SARS-COV-2 ANTIBODIES IN IMMUNOGLOBULIN PRODUCTS (2021) (1)
- Dengue and Zika: The Complexities of Being Related. (2019) (1)
- NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine (2021) (1)
- Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment (2021) (1)
- Choosing the right tool for the job: A comprehensive assessment of serological assays for SARS-CoV-2 as surrogates for authentic virus neutralization (2021) (1)
- Production and characterization of HER2-displaying budded virus-like particles and their potential as cancer vaccines (2018) (1)
- Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population (2022) (1)
- The effects of rapid mass vaccination against SARS-CoV-2 and its Variants-of-Concern: Evidence from an early VoCs hotspot (2021) (1)
- Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H 1 N 1 Influenza Virus Vaccination (2018) (1)
- Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2 (2022) (1)
- Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination (2022) (1)
- SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants (2022) (1)
- Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach (2022) (1)
- Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2 (2021) (1)
- Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice (2023) (1)
- influenza virus vaccine induces broadly reactive antibody responses 1 against H 7 N 9 in humans 2 (2014) (1)
- Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner (2021) (1)
- Detection of Velogenic Avian Paramyxoviruses in Rock Doves in New York City, New York (2021) (1)
- 20th International Conference on Emerging Infectious Diseases in the Pacific Rim Organized by the United States-Japan Cooperative Medical Sciences Program (USJCMSP) (2019) (1)
- Building a Resilient Scientific Network for COVID-19 and Beyond (2022) (1)
- Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer (2022) (1)
- A public broadly neutralizing antibody class targets a membrane-proximal anchor epitope of influenza virus hemagglutinin (2021) (1)
- Stopping emerging influenza viruses at their origin. (2017) (1)
- The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (2021) (1)
- Generation of a high yield vaccine backbone for influenza B virus in embryonated chicken eggs (2023) (0)
- Contents Category: Animal Viruses-Negative-strand RNA 4 (2013) (0)
- To our readers: Important notice (2020) (0)
- Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cell (VIR5P.1148) (2015) (0)
- A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in ferrets (2016) (0)
- Poor Prognosis for Puumala Virus Infections Predicted by Lymphopenia and Dyspnea (2023) (0)
- Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation (2021) (0)
- MHC class II proteins mediate cross-species entry of bat influenza viruses (2019) (0)
- IGHV4-34 B-Cell Receptor Immunoglobulins from CLL Stereotyped Subset 4 React with Influenza A Virus: Requirement for IGHV-D-J/Iglv-J Rearrangement and Isotype Switching to IgG (2014) (0)
- A universal influenza virus vaccine strategy targeting the conserved stalk domain of the hemagglutinin (2018) (0)
- Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination (2022) (0)
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Titer Levels in Pregnant Individuals After Infection, Vaccination, or Both. (2023) (0)
- Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies (2023) (0)
- An In Vitro Microneutralization Assay for Influenza Virus Serology (2022) (0)
- A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice (2022) (0)
- High Precursor Frequency and Promiscuity in Αβ T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope (2020) (0)
- Editorial Board (2016) (0)
- Natural H7N9 infection in humans boosts cross-group stalk-specific antibody responses broadly cross-reactive to heterosubtypic influenza hemagglutinins from both group 1 and group 2 (2017) (0)
- SARS-CoV-2 vaccines in development (2020) (0)
- Maternal cytokine response after SARS-CoV-2 infection during pregnancy (2022) (0)
- Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity (2022) (0)
- Erratum: Sunwoo, S.-Y. et al. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies. Vaccines 2018, 6(3), 64 (2018) (0)
- Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot (2022) (0)
- Longitudinal analyses of human sera reveal expansions of antibody titers specific to previously-encountered pandemic and seasonal influenza viruses (P6366) (2013) (0)
- High-Af fi nity H 7 Head and Stalk Domain – Speci fi c Antibody Responses to an Inactivated In fl uenza H 7 N 7 Vaccine After Priming With Live Attenuated In fl uenza Vaccine (2015) (0)
- F-101 A hemagglutinin stalk-based universal influenza virus vaccine (2019) (0)
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants (2023) (0)
- Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts (2019) (0)
- Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections. (2023) (0)
- A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial (2020) (0)
- Editorial Board (2016) (0)
- The human antibody response to influenza A virus infection and vaccination (2019) (0)
- Newcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses (2015) (0)
- Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination (2022) (0)
- Universal Antibody Targeting the Highly Conserved Fusion Peptide Induces Antibody-Dependent Cellular Cytotoxicity Against Diverse Strains of Both Influenza Types A and B Viruses (2021) (0)
- A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice (2022) (0)
- Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report (2022) (0)
- A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies (2017) (0)
- Viral immunity: Basic mechanisms and therapeutic applications—a Keystone Symposia report (2023) (0)
- Correction: An In Vitro Microneutralization Assay for Influenza Virus Serology. (2022) (0)
- Ion Efflux and Influenza Infection Trigger NLRP3 Inflammasome Signaling in Human Dendritic Cells (2015) (0)
- TCRab motifs is established in unvaccinated children who seroconvert after infection (2022) (0)
- Novel correlates of protection against pandemic H1N1 influenza A virus infection (2019) (0)
- Cryo-EM Tomographic Analysis of a Universal Influenza Virus Vaccine Candidate (2017) (0)
- AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets (2021) (0)
- Subtype Hemagglutinin Expressing a North American Lineage H7 Recombinant Newcastle Disease Virus Novel H7N9 Influenza Virus by Induction of Cross-Reactive Antibodies to (2014) (0)
- A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains (2019) (0)
- Two recent publications report the design of immunogens based on the conserved stalk domain of the influenza virus hemagglutinin. These new ''headless'' hemagglutinin constructs recapitulate the epitopes recognized by broadly neutralizing antibodies and induce broadly protective/heterosubtypic immun (2015) (0)
- We need to keep an eye on avian influenza (2023) (0)
- Broadly Neutralizing Antibodies Against Conserved Epitopes of the Hemagglutinin Head are Robustly Recalled by a Novel H1N1 Virus (2020) (0)
- Berichtigung: Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine (2021) (0)
- Mpox vaccine and infection-driven human immune signatures (2023) (0)
- Editorial overview: Tough targets. (2018) (0)
- A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy (2023) (0)
- Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins (2022) (0)
- Integration of Transcriptome and Cell Surface Protein Expression by LinQ-View Identifies Unique Immune Subpopulations (2021) (0)
- High Initial Titres of Anti-Spike Antibodies following SARS-CoV-2 Infection is Associated with Faster Decay Rates at Four Months Follow-Up (2021) (0)
- Antibody idiotype plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity (ADCC) against influenza A virus (2016) (0)
- Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells (2023) (0)
- SARS-CoV-2 Infection in Children Does Not Necessitate Establishment of Adaptive SARS- CoV-2-Specific Immunological Memory (2021) (0)
- High levels of endemic coronaviruses reactive CD4+ T cells in SARS-CoV-2 seronegative health care workers (2021) (0)
- Protection Against Influenza B Viruses by Human Monoclonal Antibodies that Target the Neuraminidase Active Site (2020) (0)
- Vaccination with recombinant neuraminidase protects against influenza virus infection in mice (2016) (0)
- Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk-Directed Antibody Response. (2023) (0)
- SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants (2022) (0)
- Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control (2021) (0)
- Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice (2017) (0)
- Dirk Domains Derived from Different Subtypes Hemagglutinins : Globular Head and Stalk Influenza Viruses Expressing Chimeric (2012) (0)
- Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (0)
- PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients (2023) (0)
- B cell convergence to distinct broadly reactive epitopes revealed by chimeric hemagglutinin vaccination (2022) (0)
- Defining cellular correlates of protection and vaccine failure to influenza across two human cohorts (2021) (0)
- PigsVirus Transmission in Guinea Recombinant IgA Is Sufficient To Prevent (2014) (0)
- Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site (2022) (0)
- Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial (2021) (0)
- Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner (2022) (0)
- Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations (2023) (0)
- PLOS Pathogens 2017 Reviewer and Editorial Board Thank You (2018) (0)
- Resilient Fc-Effector Functions Across SARS-CoV-2 Variants of Concern Following mRNA-1273 Vaccination (2021) (0)
- 1 1 Vaccination with B . 1 . 1 . 7 , B . 1 . 351 and P . 1 variants protects mice from challenge 2 with wild type SARS-CoV-2 3 4 (2021) (0)
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City (2020) (0)
- Quantitative, molecular-level analysis of the serum antibody repertoire reveals unanticipated features of the response to seasonal influenza vaccination (2016) (0)
- COVID-19 Infection Induces Substantial Memory B Cell Maturation to Non-Neutralizing Viral Targets (2021) (0)
- Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes (2017) (0)
- An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination (2023) (0)
- Impact of pre-existing specific influenza antibodies as a determinant of disease severity on influenza virus infected patients: a multicenter observational cohort study (2020) (0)
- Activity of human serum antibodies in a hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay (2020) (0)
- Fighting influenza through hemagglutinin diversity (2019) (0)
- Obesity outweighs antibody responses generated by an aduvanted H7N9 influenza vaccine and fails to protect mice from influenza infection (2016) (0)
- Monoclonal antibodies targeting the influenza virus N6 neuraminidase (2021) (0)
- Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV (2022) (0)
- Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021 (2022) (0)
- Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model (2022) (0)
- Bivalent COVID-19 booster vaccines induce cross-reactive but not BA.5-specific antibodies in polyclonal serum (2023) (0)
- Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
- The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination (2022) (0)
- Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection (2017) (0)
- Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial (2023) (0)
- Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice (2022) (0)
- Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses (2021) (0)
- OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study (2022) (0)
- Understanding memory B cell responses to a chimeric-based universal influenza virus vaccine candidate (2020) (0)
- Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
- OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment (2021) (0)
- Natural H3N2 influenza A infection in humans expands memory B cells specific for the hemagglutinin stalk domain (2016) (0)
- The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines (2022) (0)
This paper list is powered by the following services:
Other Resources About Florian Krammer
What Schools Are Affiliated With Florian Krammer?
Florian Krammer is affiliated with the following schools:
